Renal Cell Carcinoma

Clear cell and non-clear cell subtypes, VHL–HIF pathway biology, adjuvant therapy (LITESPARK-022), IMDC risk stratification, and IO plus VEGFR-TKI combination therapies

Key Points

• Renal cell carcinoma (RCC) accounts for ~81,800 new cases and ~14,890 deaths in the US in 2024; ~90% are clear cell RCC (ccRCC), driven by VHL inactivation and HIF pathway upregulation.
• Most RCC is now discovered incidentally on imaging; the classic triad of flank pain, hematuria, and palpable mass is seen in <10% of patients.
• Partial nephrectomy (nephron-sparing) is preferred over radical nephrectomy for T1 tumors when technically feasible.
• Pembrolizumab + belzutifan (LITESPARK-022) is the new adjuvant standard for intermediate-high to high-risk ccRCC after nephrectomy — FDA approved June 2026 (DFS HR 0.72, p=0.0003).
• IMDC risk score (0 = favorable; 1–2 = intermediate; 3–6 = poor) guides first-line systemic therapy selection for metastatic disease.
• IO + VEGFR-TKI combinations (pembrolizumab + axitinib, lenvatinib + pembrolizumab, nivolumab + cabozantinib) are favored for all IMDC risk groups in the metastatic setting.
• Belzutifan (HIF-2α inhibitor) is approved for VHL disease-associated RCC, as adjuvant therapy combined with pembrolizumab (LITESPARK-022, June 2026), and for metastatic RCC after prior IO + VEGFR-TKI therapy (LITESPARK-005).

Epidemiology & Subtypes

Renal cell carcinoma is the most common kidney cancer in adults, accounting for ~90% of all kidney malignancies. In 2024, approximately 81,800 new cases and 14,890 deaths were projected in the US. The male-to-female ratio is approximately 1.7:1. Incidence has been rising over the past 40 years, largely driven by incidental detection on imaging performed for other indications — the majority of RCC is now discovered at localized stage. Histologic subtypes: • Clear cell RCC (ccRCC): ~70–75% of RCC. Characterized by glycogen- and lipid-rich cytoplasm appearing clear on H&E. VHL tumor suppressor…

Molecular Biology & Hereditary Syndromes

The molecular pathogenesis of ccRCC is dominated by the VHL–HIF pathway: • VHL inactivation: The VHL tumor suppressor gene (chromosome 3p25) is inactivated in >90% of sporadic ccRCC through mutation, deletion, or promoter methylation. VHL protein normally targets HIF-1α and HIF-2α for proteasomal degradation under normoxic conditions. • HIF-1α/2α stabilization: Loss of VHL leads to accumulation of HIF transcription factors, which drive expression of VEGF, PDGF, EPO, GLUT1, and CAIX — promoting angiogenesis, glucose uptake, and erythropoiesis. This is the rationale for VEGF-targeted therapy.…

Clinical Presentation & Diagnosis

The classic presentation triad of flank pain, gross hematuria, and palpable abdominal mass now occurs in fewer than 10% of patients with RCC — reflecting the predominance of incidental detection. Most common presentations: • Incidental renal mass: Found on ultrasound, CT, or MRI performed for unrelated indications (~60–70% of newly diagnosed RCC). Solid enhancing renal masses are malignant in ~80–85% of cases at surgery. • Gross or microscopic hematuria: Painless hematuria prompting imaging evaluation. • Flank or abdominal pain: From hemorrhage into the tumor, renal capsule distension, or…

Localized Disease Treatment

Treatment of localized RCC is primarily surgical, with active surveillance and ablation as alternatives in selected patients: Partial nephrectomy (PN) — nephron-sparing surgery (NSS): • Strongly preferred for T1a (≤4 cm) and recommended for T1b (4–7 cm) tumors where technically feasible. • Preserves renal function (critical given association of chronic kidney disease with cardiovascular mortality), with equivalent cancer-specific survival to radical nephrectomy. • Robotic-assisted partial nephrectomy is standard at most high-volume centers. • Imperative PN (T2, solitary kidney, bilateral…

Adjuvant Therapy After Nephrectomy

Two FDA-approved adjuvant regimens are available for high-risk clear cell RCC after nephrectomy. Patient selection is critical: intermediate-high to high-risk disease — defined as pT2 Grade 4, pT3, pT4, or pN+ — and patients rendered no evidence of disease (NED) after resection of solitary M1 lesions are candidates for adjuvant therapy. **Pembrolizumab + Belzutifan (LITESPARK-022) — FDA Approved June 2026 [New Standard]:** LITESPARK-022 randomized 1,001 patients with intermediate-high to high-risk ccRCC (pT2 Grade 4, pT3–4, or pN+) after nephrectomy to pembrolizumab + belzutifan versus…

Metastatic RCC Treatment

Systemic therapy for metastatic RCC is guided by IMDC (International Metastatic RCC Database Consortium) risk stratification: IMDC risk factors (1 point each): Karnofsky PS <80%, <1 year from diagnosis to systemic treatment, hemoglobin below LLN, corrected calcium above ULN, neutrophils above ULN, platelets above ULN. • Favorable risk (0 factors): Median OS ~43–48 months • Intermediate risk (1–2): Median OS ~22–27 months • Poor risk (≥3): Median OS ~8–10 months First-line systemic therapy (ccRCC): • Nivolumab + ipilimumab (CheckMate 214): FDA approved 2018; 8-year update — ~45% of…